348640-18-6 Usage
Core structure
2-(5-methoxy-1H-indol-3-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine has a complex structure with a pyrrolopyridine core.
Tosyl group
The compound has a tosyl group attached at one end, which is a sulfonate ester.
Methoxy-indolyl group
The compound has a methoxy-indolyl group at the other end, which contains a methoxy substituent.
Pharmaceutical applications
2-(5-methoxy-1H-indol-3-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine has potential pharmaceutical applications due to its unique structure and properties.
Medicinal chemistry research
The compound may be used in medicinal chemistry research for the development of new drugs targeting specific biological pathways or processes.
Materials science
The compound could be of interest in the field of materials science for the synthesis of novel organic compounds with advanced functions or properties.
Check Digit Verification of cas no
The CAS Registry Mumber 348640-18-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,8,6,4 and 0 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 348640-18:
(8*3)+(7*4)+(6*8)+(5*6)+(4*4)+(3*0)+(2*1)+(1*8)=156
156 % 10 = 6
So 348640-18-6 is a valid CAS Registry Number.
InChI:InChI=1/C23H19N3O3S/c1-15-5-8-18(9-6-15)30(27,28)26-22(12-16-4-3-11-24-23(16)26)20-14-25-21-10-7-17(29-2)13-19(20)21/h3-14,25H,1-2H3
348640-18-6Relevant articles and documents
Design of potent IGF1-R inhibitors related to bis-azaindoles
Nemecek, Conception,Metz, William A.,Wentzler, Sylvie,Ding, Fa-Xiang,Venot, Corinne,Souaille, Catherine,Dagallier, Anne,Maignan, Sebastien,Guilloteau, Jean-Pierre,Bernard, Francois,Henry, Alain,Grapinet, Sandrine,Lesuisse, Dominique
, p. 100 - 106 (2011/03/19)
From an azaindole lead, identified in high throughput screen, a series of potent bis-azaindole inhibitors of IGF1-R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis. Although the resulting compounds produced the expected improved potency, the model was not validated by the co-crystallization experiments with IGF1-R.